Amy E. Tapper
Corporate Officer/Principal presso IMAGO BIOSCIENCES, INC.
Profilo
Amy E.
Tapper is a professional with a doctorate degree from Boston University and an undergraduate degree from Boston College.
She is currently the Senior VP-Chemistry, Manufacturing & Controls at Imago BioSciences, Inc. She was previously the Senior Vice President at FerroKin BioSciences, Inc. from 2008 to 2012.
Posizioni attive di Amy E. Tapper
| Società | Posizione | Inizio |
|---|---|---|
| IMAGO BIOSCIENCES, INC. | Corporate Officer/Principal | 01/10/2012 |
Precedenti posizioni note di Amy E. Tapper
| Società | Posizione | Fine |
|---|---|---|
FerroKin BioSciences, Inc.
 FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Corporate Officer/Principal | 01/01/2012 |
Formazione di Amy E. Tapper
| Boston University | Doctorate Degree |
| Boston College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
FerroKin BioSciences, Inc.
FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Health Technology |
Imago BioSciences, Inc.
 Imago BioSciences, Inc. BiotechnologyHealth Technology Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA. | Health Technology |
- Borsa valori
- Insiders
- Amy E. Tapper
